CDK2 Positively Regulates Aerobic Glycolysis by Suppressing SIRT5 in Gastric Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Jun 14

PMID 29896817

Citations 38

Authors

Zhenyong Tang

Lei Li

Yuntian Tang

Dongyi Xie

Kun Wu

Weiyuan Wei

Qiang Xiao

Affiliations

Soon will be listed here.

Abstract

Although significant progress has been made in the diagnosis and treatment of gastric cancer, the overall survival rate of the disease remains unchanged at approximately 20%-25%. Thus, there is an urgent need for a better understanding of the molecular biology aspects of the disease in the hope of discovering novel diagnosis and treatment strategies. Recent years have witnessed decisive roles of aberrant cancer cell metabolism in the maintenance of malignant hallmarks of cancers, and cancer cell metabolism has been regarded as a novel target for the treatment of cancer. CDK2, a cell cycle-dependent kinase that usually regulates cell cycle progression and the DNA damage response, is reported to be upregulated in many cancers. However, little is known about its role in cancer cell metabolism. In the present study, we showed that silencing CDK2 inhibited the aerobic glycolytic capacity of gastric cancer cell lines. Mechanism explorations showed that silencing CDK2 increased expression of the SIRT5 tumor suppressor. In addition, the physiological roles of SIRT5 in the regulation of proliferation and glycolysis were studied in gastric cancer cells. Taken together, the present study uncovered novel roles of the CDK2/SIRT5 axis in gastric cancer and suggests future studies concerning gastric cancer cell metabolism.

Citing Articles

Emerging roles of mitochondrial sirtuin SIRT5 in succinylation modification and cancer development.

Ke Z, Shen K, Wang L, Xu H, Pan X, Qian Z Front Immunol. 2025; 16:1531246.

PMID: 39944690 PMC: 11814216. DOI: 10.3389/fimmu.2025.1531246.

Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z Theranostics. 2024; 14(17):6726-6767.

PMID: 39479446 PMC: 11519805. DOI: 10.7150/thno.100667.

Activation and inhibition of sirtuins: From bench to bedside.

Fiorentino F, Fabbrizi E, Mai A, Rotili D Med Res Rev. 2024; 45(2):484-560.

PMID: 39215785 PMC: 11796339. DOI: 10.1002/med.22076.

Sirtuin insights: bridging the gap between cellular processes and therapeutic applications.

Kamal S, Babar S, Ali W, Rehman K, Hussain A, Akash M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9315-9344.

PMID: 38976046 DOI: 10.1007/s00210-024-03263-9.

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Su M, Lee A, Zhang W, Maeser D, Gruener R, Deng Y Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794139 PMC: 11124089. DOI: 10.3390/ph17050569.

References

Moon Y, Jeung H, Rha S, Yoo N, Roh J, Noh S . Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Ann Surg Oncol. 2007; 14(10):2730-7. DOI: 10.1245/s10434-007-9479-4. View

Lunt S, Vander Heiden M . Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011; 27:441-64. DOI: 10.1146/annurev-cellbio-092910-154237. View

Yu B, Xie J . Identifying therapeutic targets in gastric cancer: the current status and future direction. Acta Biochim Biophys Sin (Shanghai). 2015; 48(1):90-6. PMC: 4689156. DOI: 10.1093/abbs/gmv084. View

Wang S, Gu W . To be, or not to be: functional dilemma of p53 metabolic regulation. Curr Opin Oncol. 2013; 26(1):78-85. PMC: 3968813. DOI: 10.1097/CCO.0000000000000024. View

Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E . The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004; 64(7):2627-33. DOI: 10.1158/0008-5472.can-03-0846. View

Houtkooper R, Pirinen E, Auwerx J . Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012; 13(4):225-238. PMC: 4872805. DOI: 10.1038/nrm3293. View

Collins K, Jacks T, Pavletich N . The cell cycle and cancer. Proc Natl Acad Sci U S A. 1997; 94(7):2776-8. PMC: 34145. DOI: 10.1073/pnas.94.7.2776. View

Jeong S, Xiao C, Finley L, Lahusen T, Souza A, Pierce K . SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013; 23(4):450-63. PMC: 3650305. DOI: 10.1016/j.ccr.2013.02.024. View

Sun S, Li H, Chen J, Qian Q . Lactic Acid: No Longer an Inert and End-Product of Glycolysis. Physiology (Bethesda). 2017; 32(6):453-463. DOI: 10.1152/physiol.00016.2017. View

10.

Csibi A, Fendt S, Li C, Poulogiannis G, Choo A, Chapski D . The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013; 153(4):840-54. PMC: 3684628. DOI: 10.1016/j.cell.2013.04.023. View

11.

Bensaad K, Tsuruta A, Selak M, Vidal M, Nakano K, Bartrons R . TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006; 126(1):107-20. DOI: 10.1016/j.cell.2006.05.036. View

12.

Xiangyun Y, Xiaomin N, Linping G, Yunhua X, Ziming L, Yongfeng Y . Desuccinylation of pyruvate kinase M2 by SIRT5 contributes to antioxidant response and tumor growth. Oncotarget. 2016; 8(4):6984-6993. PMC: 5351684. DOI: 10.18632/oncotarget.14346. View

13.

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M . Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014; 20(38):13842-62. PMC: 4194567. DOI: 10.3748/wjg.v20.i38.13842. View

14.

Stegh A . Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils. Expert Opin Ther Targets. 2012; 16(1):67-83. PMC: 3291789. DOI: 10.1517/14728222.2011.643299. View

15.

Yu J, Li J, Chen Y, Cao W, Lu Y, Yang J . Snail Enhances Glycolysis in the Epithelial-Mesenchymal Transition Process by Targeting FBP1 in Gastric Cancer. Cell Physiol Biochem. 2017; 43(1):31-38. DOI: 10.1159/000480314. View

16.

Liu F, Wang L, Wang Q, Han P, Zhuang W, Li M . miR-302b regulates cell cycles by targeting CDK2 via ERK signaling pathway in gastric cancer. Cancer Med. 2016; 5(9):2302-13. PMC: 5055145. DOI: 10.1002/cam4.818. View

17.

Levine A, Oren M . The first 30 years of p53: growing ever more complex. Nat Rev Cancer. 2009; 9(10):749-58. PMC: 2771725. DOI: 10.1038/nrc2723. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Zhang X, Qin Z, Wang J . The role of p53 in cell metabolism. Acta Pharmacol Sin. 2010; 31(9):1208-12. PMC: 4002322. DOI: 10.1038/aps.2010.151. View

20.

Sherr C, Beach D, Shapiro G . Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2015; 6(4):353-67. PMC: 4821753. DOI: 10.1158/2159-8290.CD-15-0894. View